Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Bristol-Myers Squibb Company is a global biopharmaceutical firm focused on discovering, developing, and delivering innovative medicines for a range of serious diseases. With a rich history dating ...

Earlier this year, BMS also jettisoned a bispecific molecule it licensed from Immatics for $150 million upfront in late 2021.

SHANGHAI, Dec. 19, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ...

Bristol-Myers Squibb Company ( NYSE:BMY ) has announced that it will be increasing its periodic dividend on the 3rd ...

The strategic fit with BMS specialisms, growth culture and ambition to deliver exceptional client solutions makes this a ...

BMS CAT, a leading provider of comprehensive disaster recovery and restoration services, proudly announces the successful ...

View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company.